• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Aciphex

Quote




Anonymous said:
Pricara's weighting is now only 10%. Marketing leaves us a message stating lots of new promo items...what in the world is going on?
Click to expand...

As the drug approaches patent expiration in a generic infested market, the company is looking to drive down costs associated with ACX (fewer samples, rebate cards, etc) and hopefully hang on to the little remaining market share that it still has for a few more months. If the targets are not Rx'ing after 13 years, they won't write it in the next 6 months! I believe that the Janssen folks are dedicating their efforts to the promotion of 2 newer medications with significant future earnings potential. Must be fun?
 




From an article yesterday on J&J's Q1 2012 earnings:

"Other Pharmaceutical products declined 7.9% on an operational basis due primarily to divestitures and lower sales of ACIPHEX/PARIET and EPREX due to the impact of generic competition."
 








Top Bottom
Back
Quote